•
The TPG-National Payor Roundtable (TPG-NPRT) focuses on market access programs within the United States.
The JeSTARx Group provides evidence-based research and support to the Healthcare Industry. • Third most growth: Cardiovascular/heart disease (6); Cancer/oncology (4); and Diabetes (3);
• Other areas included: Biosimilars, Immunomodulators; and Orphan diseases.
• As the population ages and healthcare costs continue to grow, payors will change the ways they manage their formularies.
• The environment for P&T Committee decision making in managed care is undergoing a series of changes.
• Payor medical directors and pharmacy directors, who commonly serve as P&T Committee members, have a distinct understanding and opinions as to how to alter the process to adapt to these influences. • Most were happy with their plan's medical benefit management, desired changes included:
Conclusions
• Most advisors were happy with their pharmacy benefit design, the most requested changes were more restrictive management programs; followed by changes in tiers/copays ( Figure 6 ). 
